ArticleFrontiers in psychology2025
Patient perspectives on epidermal growth factor receptor inhibitor-induced skin toxicities: a qualitative study.
Article in Frontiers in psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study systematically explored the experience and supportive care needs of patients with cancer developing skin toxicity following Epidermal Growth Factor Receptor Inhibitor (EGFRI) treatment. Methods: A descriptive qualitative study was conducted. A total of 9 patients with cancer recruited from a single tertiary hospital in Zhejiang Province between July and August 2024 participated in semi-structured interviews. Data were analyzed using Colaizzi's seven-step method to systematically derive themes related to patients' experiences and care needs. Results: This study extracted a total of five themes and thirteen sub-themes, which included adverse physiological experiences, coexistence of negative and positive emotional experiences, impacts on daily life, diverse coping styles, and desire for medical support and help. Conclusion: Clinical staff should prioritize attention to the physical and psychological distress experienced by patients with cancer with EGFRI-induced skin toxicities. Implementing enhanced symptom evaluation and management, providing tailored psychological support, and offering professional guidance can help patients effectively cope with their symptoms and foster their self-growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.